samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Stoelzle Glass Group division Pharma – Health & Safety expands its product portfolio with Type II glass

Stölzle Glass Group



Due to its numerous positive characteristics, glass can be defined as the first choice of packaging material for many products, either for food, beverages or pharmaceuticals. Glass containers are chemically inert, can easily be heated and sterilized and are suitable to protect the content from contamination. The most common types of glass used in the pharmaceutical industry are Type I, Type II and Type III which are determined by their degree of hydrolytic resistance.



Over the past year Stoelzle R&D Team worked on the development of an innovative, resource-efficient, safe and stable process for Type II glass production used for acidic and neutral aqueous preparations be it parenteral or non-parenteral.

“Our intention was to develop a new process for inner treatment of soda silica glass to reduce the main weakness of the current two existing processes regarding stability and safety and to develop a process which also fits smaller bottles by enabling optimal dosing of the treatment” states Mr. Alexander Stern, CSCO Stoelzle Glass Group & Head of BU Pharma.



“In line with our goal of being the first-choice partner for the global pharmaceutical industry we have been working on broadening our range of pharma primary packaging to better serve our clients’ needs. Adhering to our overall Group’s sustainability goals, we developed a process, which ensures a consistent high quality, guarantees a high level of work safety in production with a minimum impact on the environment”, explains Mrs. Antonia Karamat, Deputy. Global Sales Director BU Pharma & Sales Director Medical & Laboratory.

Dr. Niklas Zwettler, Head of R&D at Stoelzle Glass Group adds: “With our process, we also aimed to overcome difficulties that other treatment technologies face with small containers sizes. Extensive laboratory analysis and inline samplings of container sizes ranging from 6 to 250 ml showed a good stability of our process over a wide range of filling volumes and adherence to all requirements of US and European Pharmacopoeias for Type II Glass.

Close cooperation between our engineers and our production specialists during the development process allows us to set a date for industrial production start-up by mid-2021. With already produced industrial samples, full production of Stoelzle Type II is aimed to start June 2021 in one of Stoelzle pharma dedicated plants in Köflach, Austria. The plant has two furnaces with a daily capacity of 270 tons of glass. Currently, around 1.5 billion pieces of white, amber and green packaging glass are produced annually on eleven fully automated production lines.
phone +43 1 41565
email Doris.Marka@stoelzle.com
web https://www.stoelzle.com/
email Stoelzle Oberglas GmbH Keißlergasse 26-28 A-1140 Wien
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition

First patient dosed in the CYAD-211 Phase 1 IMMUNICY-1 trial. Preclinical results for CYAD-211 for multiple myeloma showed robust antitumor activity with no demonstrable evidence of Graft-versus-Host Disease Company discontinues the development of first-generation, autologous CAR T candidate CYAD-01 based on clinical futility observed to date from the Phase 1 THINK trial Preliminary data from CYCLE-1 trial evaluating next-generation autologous CYAD-02 in r/r AML / MDS patients showed encouraging clinical signals, including a high-risk MDS patient treated at dose level 3 who achieved an objective marrow complete response; dose level 3 cohort of the CYCLE-1 trial is ongoing Management to hold a conference call later today, December 7, at 1 p.m. CET/ 7 a.m. ET
More info >>


White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement